Return of the psychedelics: Psilocybin for treatment resistant depression

doi:10.1016/j.ajp.2016.08.010

Asian Journal of Psychiatry

Volume 24, December 2016, Pages 51-52

https://doi.org/10.1016/j.ajp.2016.08.010 Get rights and content

Abstract

Psilocybin, the clinically most researched classic psychedelic has recently been tested for its safety and efficacy in a clinical population of treatment resistant depression. The efficacy of psilocybin in clinical depression previously demonstrated in the elecrophysiologic and neuroimaging findings as also in neuropsychological assessments is further validated by the findings of this rigorously conducted randomized trial. Mechanism of action of psilocybin and efficacy in treatment resistant depression are discussed in this paper. Ethical issues of conducting clinical trials with psychedelics are also discussed with particular emphasis on their relative safety and absence of addiction potential. Implications of these issues for conduct of larger trials for establishing risk benefit ratio in treatment resistant depression are further suggested.

References (9)

R.L. Carhart-Harris et al.
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Lancet Psychiatry
(2016)
R. Kraehenmann et al.
The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity
Neuroimage Clin.
(2016)
M.C. Mithoefer et al.
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA
Lancet Psychiatry
(2016)
F. Tylš et al.
Psilocybin–summary of knowledge and new perspectives
Eur. Neuropsychopharmacol.
(2014)

There are more references available in the full text version of this article.

Cited by (17)

What's around the corner in the niche of psychopharmacotherapy of major depressive disorder?
2019, Asian Journal of Psychiatry
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
2019, Pharmacology and Therapeutics
Citation Excerpt :
In response to promising results in the treatment of depression with classic psychedelics (both within and outside of cancer contexts), a number of reviews and commentaries have been published. A commonality is acknowledgement of promising findings but recognition of the early stages of this research and the need for larger studies investigating methodological variations, in particular the need for randomized research in non-cancer related treatment-resistant depression, continued research on potential risks, and additional research on potential mechanisms (e.g., dos Santos et al., 2016; Mahapatra and Gupta, 2017; Patra, 2016; Cowen, 2016; McCorvy et al., 2016). A challenge not typically recognized in commentaries is that, despite widespread agreement that systematic and rigorous following is essential, substantial funding is required for large trials and mechanistic studies, and to date, federal funding for such follow-up research has not been provided.
The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic hallucinogens), which are serotonin 2A receptor (5-HT_2AR) agonists such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Classic psychedelics have been administered as sacraments since ancient times. They were of prominent interest within psychiatry and neuroscience in the 1950s to 1960s, and during this time contributed to the emergence of the field of molecular neuroscience. Promising results were reported for treatment of both end-of-life psychological distress and addiction, and classic psychedelics served as tools for studying the neurobiological bases of psychological disorders. Moreover, classic psychedelics were shown to occasion mystical experiences, which are subjective experiences reported throughout different cultures and religions involving a strong sense of unity, among other characteristics. However, the recreational use of classic psychedelics and their association with the counterculture prompted an end to human research with classic psychedelics in the early 1970s. We provide the most comprehensive review of epidemiological studies of classic psychedelics to date. Notable among these are a number of studies that have suggested the possibility that nonmedical naturalistic (non-laboratory) use of classic psychedelics is associated with positive mental health and prosocial outcomes, although it is clear that some individuals are harmed by classic psychedelics in non-supervised settings. We then review recent therapeutic studies suggesting efficacy in treating psychological distress associated with life-threatening diseases, treating depression, and treating nicotine and alcohol addictions. We also describe the construct of mystical experience, and provide a comprehensive review of modern studies investigating classic psychedelic-occasioned mystical experiences and their consequences. These studies have shown classic psychedelics to fairly reliably occasion mystical experiences. Moreover, classic-psychedelic-occasioned mystical experiences are associated with improved psychological outcomes in both healthy volunteer and patient populations. Finally, we review neuroimaging studies that suggest neurobiological mechanisms of classic psychedelics. These studies have also broadened our understanding of the brain, the serotonin system, and the neurobiological basis of consciousness. Overall, these various lines of research suggest that classic psychedelics might hold strong potential as therapeutics, and as tools for experimentally investigating mystical experiences and behavioral-brain function more generally.
Abuse of magic mushroom, peyote cactus, LSD, khat, and volatiles
2019, Critical Issues in Alcohol and Drugs of Abuse Testing
Although less common than abuse of marijuana and cocaine, abuse of magic mushroom, peyote cactus, lysergic acid diethylamide (LSD), khat, and volatiles is observed in the United States. Eating wild mushroom is dangerous because misidentification of toxic mushroom as magic mushroom may be fatal. Magic mushroom contains psilocybin and psilocin but major psychedelic action of magic mushroom is due to rapid conversion of psilocybin to psilocin after ingestion. Active ingredient of peyote cactus is mescaline. Abuse of LSD was widespread in 1960s but this drug is still abused today. Khat leaves are chewed in certain parts of Africa but with migration, this product is also abused in Europe and United States. Major active ingredient of khat plant is cathinone, which is structurally and functionally similar to amphetamine. Volatile abuse is widespread among young people. Abusing volatiles containing toluene, hydrocarbons, and other compounds with highvapor pressure is injurious to health. Such abuse may even cause death.
Dangerous plants in dermatology: Legal and controlled
2018, Clinics in Dermatology
Citation Excerpt :
The psilocybe mushroom is perhaps best known for its hallucinogenic psilocybin, a monamine/indole alkaloid occurring naturally in the mushroom (Figure 8). Psilocybin is a prodrug of psilocin (4-hydroxy-dimethyltryptamine), a serotonin agonist in the human brain that can have impressive effects on perception, cognition, and emotion, producing psychosis-like clinical manifestations.206 Although it has been used for thousands of years for medicinal purposes, it is better known as a recreational drug and often viewed disparagingly by the medical field.207
The plant and mushroom kingdoms have species used for intoxication, inebriation, or recreation. Some of these species are toxic. Given that many of these plants or substances are illegal and have histories of abuse, much of the research regarding therapeutic application is based on basic science, animal studies, and traditional use. This review examines Cannabis, Euphorbia, Ricinus, Podophyllum, Veratrum, mushrooms, and nightshades, along with resveratrol and cocaine as they relate to dermatology.
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
2023, Current Reviews in Clinical and Experimental Pharmacology
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation
2023, Molecular Psychiatry

View all citing articles on Scopus

View full text

Return of the psychedelics: Psilocybin for treatment resistant depression

Abstract

Lancet Psychiatry

Neuroimage Clin.

Lancet Psychiatry

Eur. Neuropsychopharmacol.